Skip to main content
. 2022 Aug 27;24(10):1892–1901. doi: 10.1002/ejhf.2652

Figure 2.

EJHF-2652-FIG-0002-c

Effect of dapagliflozin versus placebo on symptom burden and other measures of health status by baseline New York Heart Association (NYHA) functional class. Values displayed as mean difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) assessment score between dapagliflozin and placebo groups at week 32 compared with week 0. CI, confidence interval.